TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19808926

Group type: EXPERIMENTAL
Intervention: Diabetes Interactive Diary (DID)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 130
Study: 17296645

Group type: EXPERIMENTAL
Intervention: 6MWT
Number of subjects: 10

Group type: COMPARATOR
Intervention: CPET
Number of subjects: 10
Study: 16139183

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 12126459

Group type: EXPERIMENTAL
Intervention: efavirenz 600 mg once daily without rifampicin (group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: efavirenz 800 mg once daily with rifampicin (group A-2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: rifampicin in bodyweight‐adjusted fixed‐dose combination (group B)
Number of subjects: 24
Study: 10428251

Group type: EXPERIMENTAL
Intervention: Self-administered tampon before physician-directed swabs of the cervix
Number of subjects: 93

Group type: COMPARATOR
Intervention: Physician-directed swab testing before using the self-administered tampon
Number of subjects: 93
Study: 7595108

Group type: EXPERIMENTAL
Intervention: Spinal manipulation therapy (SMT) applied by experienced physicians
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spinal manipulation therapy (SMT) applied by novice manipulators
Number of subjects: 30
Study: 2197004

Group type: COMPARATOR
Intervention: 1.5 mg.kg‐1 intramuscular codeine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4 mg.kg‐1 of ten per cent aerosol lidocaine
Number of subjects: 30
Study: 7196885

Group type: COMPARATOR
Intervention: Levamisole, 150 mg daily for 2 consecutive days per week for 6 weeks (Group I, half received levamisole, half received placebo)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Levamisole, 150 mg daily for 2 consecutive days per week for 6 weeks (Group II, all received levamisole)
Number of subjects: 2
Study: 30365412

Group type: EXPERIMENTAL
Intervention: CXL using conventional 3 mW/cm UVA irradiation for 30 minutes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CXL using accelerated 9 mW/cm UVA irradiation for 10 minutes
Number of subjects: 40
Study: 29616621

Group type: EXPERIMENTAL
Intervention: Prototype disinfectant spray (0.13% w/v benzalkonium chloride and a cooling agent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BACTROBAN® disinfectant spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control (0.9% w/v saline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive control (70% w/v isopropyl alcohol, pilot study only)
Number of subjects: 0
Study: 26492848

Group type: EXPERIMENTAL
Intervention: Delivery of interactive information via Wechat along with standard education (n = 387)
Number of subjects: 770

Group type: COMPARATOR
Intervention: Standard education (controls, n = 383)
Number of subjects: 770
Study: 24500060

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 53

Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 53
Study: 22089205

Group type: EXPERIMENTAL
Intervention: 250 mL 7.2% NaCl/6% hydroxyethyl starch (HT group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 500 mL 6% hydroxyethyl starch (IT group)
Number of subjects: 24
Study: 19737845

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention designed to produce weight loss (Look AHEAD)
Number of subjects: 15496

Group type: EXPERIMENTAL
Intervention: Pharmacological therapies for control of glycemia, hyperlipidemia, and hypertension (ACCORD)
Number of subjects: 15496

Group type: COMPARATOR
Intervention: Joint eligibility for both trials
Number of subjects: 15496
Study: 17892406

Group type: EXPERIMENTAL
Intervention: Telephone-based Glasgow Outcome Scale (GOS) assessment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Face-to-face Glasgow Outcome Scale (GOS) assessment
Number of subjects: 66
Study: 16896964

Group type: EXPERIMENTAL
Intervention: Ketamine administration
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 11990442

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Enamel Matrix Protein Derivative (EMD)
Number of subjects: 14
Study: 9449871

Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg three times daily for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo three times daily for 7 days
Number of subjects: 40
Study: 7664854

Group type: EXPERIMENTAL
Intervention: Nebulized saline (hypertonic saline 3%)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Normal saline (0.9%)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulizers (De Vilbiss Ultraneb 99 and Fisoneb)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Jet nebulizer (Pari LL with Master Compressor)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Saline concentrations (3%, 4%, 5%)
Number of subjects: 39
Study: 2651509

Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline, 10 mg twice daily (b.i.d.)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline, 10 mg b.i.d. and two puffs (400 micrograms) of budesonide, b.i.d.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Two puffs (400 micrograms) of budesonide, b.i.d.
Number of subjects: 37
Study: 1093481

Group type: EXPERIMENTAL
Intervention: Miconazole nitrate (2.0%) cream
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control vehicle
Number of subjects: 99
Study: 30428907

Group type: EXPERIMENTAL
Intervention: Exercise intervention at a local fitness center with a paid membership
Number of subjects: 76

Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 76
Study: 28939567

Group type: EXPERIMENTAL
Intervention: Prehospital administration of 180 mg ticagrelor
Number of subjects: 1862

Group type: COMPARATOR
Intervention: In-hospital administration of 180 mg ticagrelor
Number of subjects: 1862
Study: 25448245

Group type: EXPERIMENTAL
Intervention: Virtual reality-based telerehabilitation program
Number of subjects: 30

Group type: COMPARATOR
Intervention: In-clinic program (control)
Number of subjects: 30
Study: 23864112

Group type: EXPERIMENTAL
Intervention: Intervention grounded in activation principles
Number of subjects: 587

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 587
Study: 21636798

Group type: COMPARATOR
Intervention: Optimal glycemic control (A1C <6.1%)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Good glycemic control (A1C 6.1-6.9%)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Moderate glycemic control (A1C 7.0-7.9%)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Poor glycemic control (A1C ≥8.0%)
Number of subjects: 749

Group type: COMPARATOR
Intervention: A1C values ≥ 6.1% at 26 weeks' gestation
Number of subjects: 749

Group type: COMPARATOR
Intervention: A1C values ≥ 7.0% at 34 weeks' gestation
Number of subjects: 749

Group type: COMPARATOR
Intervention: Each 1% decrement in A1C before pregnancy
Number of subjects: 749

Group type: COMPARATOR
Intervention: Each 1% decrement in A1C at first antenatal visit
Number of subjects: 749

Group type: COMPARATOR
Intervention: Each 1% decrement in A1C at 26 weeks' gestation
Number of subjects: 749

Group type: COMPARATOR
Intervention: Each 1% decrement in A1C at 34 weeks' gestation
Number of subjects: 749
Study: 17397949

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (45 mg p.o.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 17063129

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 250

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 250
Study: 12807346

Group type: EXPERIMENTAL
Intervention: D-camphor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extract from fresh crataegus berries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of D-camphor and extract from fresh crataegus berries (CCC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11277825

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 3086

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3086
Study: 9551417

Group type: EXPERIMENTAL
Intervention: Treatment B (on-line conductivity ultrafiltrate kinetic modeling)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Treatment A (standard treatment with fixed dialysate conductivity)
Number of subjects: 39
Study: 8177793

Group type: EXPERIMENTAL
Intervention: Nursing interventions (physical, psychological, and social aspects of care)
Number of subjects: 1
Study: 3288866

Group type: EXPERIMENTAL
Intervention: Oral IgA-IgG (73% IgA and 26% IgG)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Control group (no oral IgA-IgG)
Number of subjects: 434
Study: 4888873

Group type: EXPERIMENTAL
Intervention: Emepronium bromide (Cetiprin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31531547

Group type: EXPERIMENTAL
Intervention: Pterygium tissue
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal conjunctival tissue
Number of subjects: 29
Study: 31209851

Group type: EXPERIMENTAL
Intervention: Topical Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel (A0.3/BPO2.5) for 48 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Vehicle for 24 weeks followed by A0.3/BPO2.5 for 24 weeks
Number of subjects: 45
Study: 28438596

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.1 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 25896108

Group type: EXPERIMENTAL
Intervention: Pentacam
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: USP
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: AS-OCT
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (non-surgery eye)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Post-surgery corneas
Number of subjects: 32
Study: 23376998

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 36

Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 36
Study: 21819552

Group type: EXPERIMENTAL
Intervention: Confidence in managing hypertension (HT)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Confidence in managing CKD with hypertension (HT+CKD)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Confidence in managing CKD, hypertension, and diabetes (CKD+HT+DM)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Achievement of pay-for-performance indicators (P4P) in patients with hypertension
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Achievement of national targets in patients with hypertension
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Achievement of P4P in patients with HT and CKD
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Achievement of national targets in patients with HT and CKD
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Achievement of P4P in patients with HT, CKD, and DM
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Achievement of national targets in patients with HT, CKD, and DM
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Confidence in managing proteinuria in CKD
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Knowledge of BP treatment thresholds in CKD
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Knowledge of BP treatment thresholds when proteinuria is factored in
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Confidence levels based on gender and age
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Achievement of P4P targets in patients treated with angiotensin modulating drugs
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Achievement of P4P targets in patients with CKD
Number of subjects: 201
Study: 19939894

Group type: EXPERIMENTAL
Intervention: CXCR4(+) tumors
Number of subjects: 823

Group type: COMPARATOR
Intervention: CXCR4(‐) tumors
Number of subjects: 823
Study: 16483360

Group type: EXPERIMENTAL
Intervention: Early surgical atlantoaxial fixation
Number of subjects: 250

Group type: COMPARATOR
Intervention: Prolonged conservative treatment
Number of subjects: 250
Study: 15143910

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg i.v. once daily (n=72)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg twice a day (n=71)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g every 6 hours (n=69)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo (n=75)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 287
Study: 11784339

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BtxA) 1000 IU
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 9257757

Group type: EXPERIMENTAL
Intervention: Levofloxacin (350 mg of levofloxacin hemihydrate)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30087196

Group type: EXPERIMENTAL
Intervention: Rehabilitation manual for home use
Number of subjects: 50

Group type: COMPARATOR
Intervention: Verbal recommendations (control group)
Number of subjects: 50
Study: 27918189

Group type: EXPERIMENTAL
Intervention: Mentalization-based therapy for parental conflict (Parenting Together)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Parents' Group (psycho-educational intervention based on Separated Parents Information Program)
Number of subjects: 30
Study: 25250291

Group type: EXPERIMENTAL
Intervention: 5% dapsone gel plus oral isotretinoin 20 mg daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: Oral isotretinoin 20 mg daily (Control group with vehicle gel)
Number of subjects: 58
Study: 23297553

Group type: EXPERIMENTAL
Intervention: Standardized electric acupuncture and massage
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rehabilitation therapy
Number of subjects: 120
Study: 20411833

Group type: EXPERIMENTAL
Intervention: Thermocycling (500 cycles at 5 ‐ 55 degrees C; dwell time of 30 seconds; transfer time of 10 seconds)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No thermocycling (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thermocycling
Number of subjects: 20
Study: 16882819

Group type: EXPERIMENTAL
Intervention: Fluticasone (2 mg via metered dose inhaler in the emergency department plus 500 microg twice daily via Diskus for 10 doses after discharge)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Oral prednisolone (2 mg/kg in the emergency department plus 5 daily doses of 1 mg/kg after discharge)
Number of subjects: 69
Study: 15600377

Group type: EXPERIMENTAL
Intervention: Serotonin-norepinephrine reuptake inhibitors (SNRIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study: 11550937

Group type: EXPERIMENTAL
Intervention: Biodegradable carmustine polymer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other regression models for censored survival data
Number of subjects: 0
Study: 9692422

Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Unfractionated heparin 7500iu
Number of subjects: 17
Study: 7871610

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin once daily (prophylaxis group, n = 176)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group without prophylaxis (n = 163)
Number of subjects: 339
Study: 3060065

Group type: EXPERIMENTAL
Intervention: Fine catheter aspiration cytology of the peritoneal cavity
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional clinical assessment (Control)
Number of subjects: 98
Study: 30790377

Group type: EXPERIMENTAL
Intervention: High understaffing
Number of subjects: 2207

Group type: EXPERIMENTAL
Intervention: Low understaffing
Number of subjects: 2207

Group type: COMPARATOR
Intervention: Sufficient staffing
Number of subjects: 2207
Study: 28806194

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-month (PP3M) treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Paliperidone palmitate 1-month (PP1M) treatment
Number of subjects: 48
Study: 25315181

Group type: EXPERIMENTAL
Intervention: Enhanced REP (customized manual/training/facilitation)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Standard REP (manual/training)
Number of subjects: 384
Study: 23269821

Group type: EXPERIMENTAL
Intervention: Advergame promoting energy-dense snacks
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Advergame promoting fruit
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Advergame promoting nonfood products
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 270
Study: 21565464

Group type: EXPERIMENTAL
Intervention: Modafinil (up to 300 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 18489665

Group type: EXPERIMENTAL
Intervention: Continuous etanercept treatment (50 mg twice weekly for 12 weeks, then 50 mg once weekly for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interrupted etanercept treatment (single round of discontinuation and re-treatment with etanercept 50 mg once weekly for the second 12 weeks)
Number of subjects: 0
Study: 16717337

Group type: EXPERIMENTAL
Intervention: Double-injection axillary brachial plexus block
Number of subjects: 90

Group type: COMPARATOR
Intervention: Midhumeral block
Number of subjects: 90
Study: 14979502

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 39
Study: 11525091

Group type: EXPERIMENTAL
Intervention: Planned vaginal delivery (VD) in non-randomised group
Number of subjects: 236

Group type: COMPARATOR
Intervention: Primary caesarean section (CS) in non-randomised group
Number of subjects: 236

Group type: COMPARATOR
Intervention: Planned caesarean section (CS) in randomized group
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Planned vaginal delivery (VD) in randomized group
Number of subjects: 236
Study: 8998184

Group type: EXPERIMENTAL
Intervention: Educational approach
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Counseling approach
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 400
Study: 8502513

Group type: COMPARATOR
Intervention: BA + PL (0.2 mg albuterol with placebo three times a day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: BA + CS (0.2 mg albuterol with budesonide three times a day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BA + CS
Number of subjects: 40
Study: 3318423

Group type: EXPERIMENTAL
Intervention: 1 g of nabumetone administered at night
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 1 g of nabumetone given at night
Number of subjects: 41

Group type: COMPARATOR
Intervention: 250 mg of naproxen in the morning and 500 mg at night
Number of subjects: 41

Group type: COMPARATOR
Intervention: Naproxen (500 mg twice daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Indomethacin (50 mg three times daily)
Number of subjects: 41
Study: 31765687

Group type: EXPERIMENTAL
Intervention: 112.5 kcal beverage
Number of subjects: 83

Group type: COMPARATOR
Intervention: 0 kcal beverage
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: High viscous beverage
Number of subjects: 83

Group type: COMPARATOR
Intervention: Low viscous beverage
Number of subjects: 83
Study: 30695080

Group type: EXPERIMENTAL
Intervention: Multiple bouts of walking
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Continuous walking
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 27471838

Group type: EXPERIMENTAL
Intervention: 300 index of reactivity (IR)
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: 500 index of reactivity (IR)
Number of subjects: 968

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study: 24912485

Group type: COMPARATOR
Intervention: Standard Dose (SD) oseltamivir
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Double Dose (DD) oseltamivir
Number of subjects: 52
Study: 22652917

Group type: EXPERIMENTAL
Intervention: Supervised off-season conditioning program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Unsupervised off-season conditioning program
Number of subjects: 44
Study: 21613353

Group type: COMPARATOR
Intervention: Testosterone (men)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Estradiol (women)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GHRH or GHRP-2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study: 19289342

Group type: EXPERIMENTAL
Intervention: Medication Therapy Management (MTM) services for hypertension and diabetes management
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no MTM services)
Number of subjects: 52
Study: 16687712

Group type: EXPERIMENTAL
Intervention: Budesonide (400 mug per day)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Budesonide and Placebo
Number of subjects: 411
Study: 15609475

Group type: EXPERIMENTAL
Intervention: Erythropoietic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise programs, educational support, counseling, energy conservation strategies
Number of subjects: 0
Study: 11291531

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 25
Study: 9433148

Group type: EXPERIMENTAL
Intervention: Grape molasses (GM) in infants with IDA
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ferrous sulfate (FS) in infants with IDA
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Grape molasses (GM) in non-anemic infants
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ferrous sulfate (FS) in non-anemic infants
Number of subjects: 56
Study: 7960548

Group type: EXPERIMENTAL
Intervention: Home automated intermittent peritoneal dialysis (IPD)
Number of subjects: 16
Study: 3236744

Group type: EXPERIMENTAL
Intervention: Topically applied dexamethasone eyedrops 0.1% with local antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin (an inhibitor of cyclooxygenase)
Number of subjects: 0